- Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
- Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
- Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Gamida Cell to Present at Upcoming January Investor Conferences
- Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Gamida Cell Added to NASDAQ Biotechnology Index
- Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares
- Gamida Cell Announces Launch of Public Offering of Ordinary Shares
- Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
Gamida Cell Ltd (GMDA:NMQ) closed at 9.36, -37.60% below its 52-week high of 15.00, set on Feb 10, 2021.
2.60Mar 16 202015.00Feb 10 2021
Markit short selling activity
|Market cap||552.17m USD|
|EPS (TTM)||-1.17 |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.